ArticlePediatric cardiology2026
Neighborhood Child Opportunity Index and Outcomes in Pediatric Pulmonary Hypertension.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of social determinants of health (SDoH) in pediatric pulmonary hypertension (PH) outcomes are inadequately characterized. We hypothesized outcomes differ according to SDoH with increased mortality in those from low Child Opportunity Index (COI) areas or non-local to our center, with public insurance, limited English proficiency and underrepresented races/ethnicities. In a single center, retrospective cohort study, pediatric PH patients with inpatient admission from 2015 to 2022 were identified using ICD-10 codes. Clinical therapies and outcomes were compared by SDoH controlling for clinical factors, admission count, and follow-up length. Of 1735 pediatric PH patients, 232 (13.4%) died. Median time to follow-up/death was 35 days (IQR 8, 241). Median age was 215 days (IQR 14, 1716) with PH groups of pulmonary arterial hypertension (22.9%), left heart disease (40.5%), lung disease (27.0%), thromboembolic (1.3%) and other (8.2%). Patients utilized ECMO (11.3%), lung transplant (1.5%), PDE5 inhibitors (31.7%), prostacyclins (3.1%), endothelin receptor antagonists (4.2%), and inhaled nitric oxide (34.9%). Therapy use did not differ by COI or race/ethnicity. Decedents had lower COI than survivors (median 61.5 vs. 69.0 p = 0.002). Mortality differed by insurance (15.5% public vs 11.7% private, p = 0.022) and race/ethnicity (highest [19.6%] in children with Black/African American race p < 0.001). 10-point COI increases had 7% lower adjusted mortality odds (95%CI 0.873, 0.987, p = 0.009). Children with Black/African American race had higher adjusted mortality odds (1.94 95%CI 1.2, 3.2 p = 0.012). In pediatric PH, lower COI and Black/African American race are independently associated with greater mortality. Findings highlight importance of studying SDoH in pediatric PH.
Indexed as
Identifiers
40753143What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.